Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.

VEGF-A levels predict outcome in ventilator-associated pneumonia

05 Jun 2018

Elevated levels of circulating vascular endothelial growth factor (VEGF)‐A are associated with early resolution of ventilator-associated pneumonia (VAP), regardless of disease severity, a study has found.

Researchers measured serum VEGF‐A levels for 7 consecutive days in 82 VAP patients. They also obtained bronchoalveolar lavage (BAL) samples from experimental mouse challenged intratracheally with Pseudomonas aeruginosa at the following time points: 24, 48 and 124 hours after bacterial challenge. Levels of VEGF‐A, tumour necrosis factor alpha (TNF‐α), interleukin (IL)‐1β, interferon‐gamma (IFNγ) and myeloperoxidase (MPO) activity were measured in the animal samples.

VEGF-A levels increased significantly on day 5. The increase was <45 percent in 36 patients and ≥45 percent in 46. Specifically, in the group of patients showing greater increase in VEGF-A levels, VAP resolution occurred with greater frequency (65.2 percent vs 36.1 percent; p=0.014) and earlier (p=0.005). These results were not pathogen-specific.

On logistic regression analysis, the likelihood of VAP resolution was threefold higher in patients with a more than 45-percent increase in VEGF-A levels on day 5 (odds ratio, 3.32; 95 percent CI, 1.33–8.25).

VEGF‐A levels in mouse BAL and lung tissue increased significantly at 124 hours. In mice pretreated with bevacizumab, VEGF‐A concentrations decreased whereas TNF‐α and MPO markedly increased.

The present data indicate that an early increase in circulating VEGF-A in patients with VAP is associated with a greater chance of a clinical resolution of disease, whereas animal experiments in mice show that levels of VEGF-A rise in parallel with the resolution of inflammation after bacterial infection. Additional clinical and mechanistic studies are needed to establish the role of VEGF-A in VAP resolution, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.